PMID- 37989717
OWN - NLM
STAT- MEDLINE
DCOM- 20240205
LR  - 20240206
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 32
IP  - 2
DP  - 2024 Feb
TI  - Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at 
      baseline: A post hoc subgroup analysis.
PG  - 273-280
LID - 10.1002/oby.23946 [doi]
AB  - OBJECTIVE: To explore the efficacy and safety of semaglutide 2.4 mg in people 
      with overweight/obesity who were also being treated with antidepressants (ADs). 
      METHODS: Across the Semaglutide Treatment Effect for People with obesity (STEP) 
      1-3 and 5 trials, adults with overweight/obesity and type 2 diabetes (STEP 2 
      only) were enrolled. People with severe major depressive disorder within 2 years 
      prior to screening or with a patient health questionnaire-9 score >/=15 at 
      screening were excluded. Participants were categorized into subgroups according 
      to baseline AD status (on/off ADs) in this post hoc exploratory analysis of the 
      STEP trials. RESULTS: Of 3683 participants randomized, 539 were on ADs at 
      baseline. Mean body weight change from baseline to week 68 was greater for 
      semaglutide versus placebo, regardless of baseline AD use. In STEP 1, for 
      participants on ADs at baseline, mean change from baseline was -15.7% with 
      semaglutide versus -0.2% with placebo and -14.7% versus -2.8% for those not on 
      ADs at baseline. Similar patterns were seen in STEP 2, 3, and 5. The prevalence 
      of adverse events (AEs) was generally similar between semaglutide and placebo in 
      participants on ADs at baseline. CONCLUSIONS: In adults with overweight/obesity, 
      semaglutide provided clinically meaningful weight loss regardless of baseline AD 
      use, with an AE profile consistent with previous studies.
CI  - (c) 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The 
      Obesity Society.
FAU - Kushner, Robert F
AU  - Kushner RF
AUID- ORCID: 0000-0002-1380-3705
AD  - Department of Medicine and Medical Education, Feinberg School of Medicine, 
      Northwestern University, Chicago, Illinois, USA.
FAU - Fink-Jensen, Anders
AU  - Fink-Jensen A
AD  - Psychiatric Centre Copenhagen and Department of Clinical Medicine, University of 
      Copenhagen, Copenhagen, Denmark.
FAU - Frenkel, Ofir
AU  - Frenkel O
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - McGowan, Barbara
AU  - McGowan B
AUID- ORCID: 0000-0003-2015-726X
AD  - Cleveland Clinic London Hospital, Portland Place Outpatient Centre, London, UK.
FAU - Goldman, Bryan
AU  - Goldman B
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Overvad, Maria
AU  - Overvad M
AD  - Novo Nordisk A/S, Soborg, Denmark.
FAU - Wadden, Thomas
AU  - Wadden T
AUID- ORCID: 0000-0002-0438-4609
AD  - Department of Psychiatry, Perelman School of Medicine, University of 
      Pennsylvania, Philadelphia, Pennsylvania, USA.
LA  - eng
GR  - Novo Nordisk A/S/
PT  - Journal Article
DEP - 20231121
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 53AXN4NNHX (semaglutide)
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - *Glucagon-Like Peptides/adverse effects
MH  - *Obesity/drug therapy
MH  - Overweight/complications/drug therapy
MH  - Treatment Outcome
MH  - Antidepressive Agents/therapeutic use
MH  - Randomized Controlled Trials as Topic
EDAT- 2023/11/22 00:42
MHDA- 2024/01/26 06:43
CRDT- 2023/11/21 22:43
PHST- 2023/09/15 00:00 [revised]
PHST- 2023/07/12 00:00 [received]
PHST- 2023/09/28 00:00 [accepted]
PHST- 2024/01/26 06:43 [medline]
PHST- 2023/11/22 00:42 [pubmed]
PHST- 2023/11/21 22:43 [entrez]
AID - 10.1002/oby.23946 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2024 Feb;32(2):273-280. doi: 10.1002/oby.23946. Epub 
      2023 Nov 21.